Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology
COVID-19 has become difficult to contain in our interconnected world. In this article, we discuss some approaches that could reduce the consequences of COVID-19. We elaborate upon the utility of camelid single-domain antibodies (sdAbs), also referred to as nanobodies, which are naturally poised to n...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2020.581076/full |
| _version_ | 1818130455311941632 |
|---|---|
| author | Abhishek Dubey Surbhi Dahiya Barry T. Rouse Sharvan Sehrawat |
| author_facet | Abhishek Dubey Surbhi Dahiya Barry T. Rouse Sharvan Sehrawat |
| author_sort | Abhishek Dubey |
| collection | DOAJ |
| description | COVID-19 has become difficult to contain in our interconnected world. In this article, we discuss some approaches that could reduce the consequences of COVID-19. We elaborate upon the utility of camelid single-domain antibodies (sdAbs), also referred to as nanobodies, which are naturally poised to neutralize viruses without enhancing its infectivity. Smaller sized sdAbs can be easily selected using microbes or the subcellular organelle display methods and can neutralize SARS-CoV2 infectivity. We also discuss issues related to their production using scalable platforms. The favorable outcome of the infection is evident in patients when the inflammatory response is adequately curtailed. Therefore, we discuss approaches to mitigate hyperinflammatory reactions initiated by SARS-CoV2 but orchestrated by immune mediators. |
| first_indexed | 2024-12-11T08:05:19Z |
| format | Article |
| id | doaj.art-7493948b89924ecba9b42c1f6a31f532 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T08:05:19Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7493948b89924ecba9b42c1f6a31f5322022-12-22T01:15:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-10-011110.3389/fimmu.2020.581076581076Perspective: Reducing SARS-CoV2 Infectivity and Its Associated ImmunopathologyAbhishek Dubey0Surbhi Dahiya1Barry T. Rouse2Sharvan Sehrawat3Department of Biological Sciences, Indian Institute of Science Education and Research Mohali, Mohali, IndiaDepartment of Biological Sciences, Indian Institute of Science Education and Research Mohali, Mohali, IndiaBiomedical and Diagnostic Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN, United StatesDepartment of Biological Sciences, Indian Institute of Science Education and Research Mohali, Mohali, IndiaCOVID-19 has become difficult to contain in our interconnected world. In this article, we discuss some approaches that could reduce the consequences of COVID-19. We elaborate upon the utility of camelid single-domain antibodies (sdAbs), also referred to as nanobodies, which are naturally poised to neutralize viruses without enhancing its infectivity. Smaller sized sdAbs can be easily selected using microbes or the subcellular organelle display methods and can neutralize SARS-CoV2 infectivity. We also discuss issues related to their production using scalable platforms. The favorable outcome of the infection is evident in patients when the inflammatory response is adequately curtailed. Therefore, we discuss approaches to mitigate hyperinflammatory reactions initiated by SARS-CoV2 but orchestrated by immune mediators.https://www.frontiersin.org/articles/10.3389/fimmu.2020.581076/fullinflammationtherapysdAbimmunoregulationviruses |
| spellingShingle | Abhishek Dubey Surbhi Dahiya Barry T. Rouse Sharvan Sehrawat Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology Frontiers in Immunology inflammation therapy sdAb immunoregulation viruses |
| title | Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology |
| title_full | Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology |
| title_fullStr | Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology |
| title_full_unstemmed | Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology |
| title_short | Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology |
| title_sort | perspective reducing sars cov2 infectivity and its associated immunopathology |
| topic | inflammation therapy sdAb immunoregulation viruses |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2020.581076/full |
| work_keys_str_mv | AT abhishekdubey perspectivereducingsarscov2infectivityanditsassociatedimmunopathology AT surbhidahiya perspectivereducingsarscov2infectivityanditsassociatedimmunopathology AT barrytrouse perspectivereducingsarscov2infectivityanditsassociatedimmunopathology AT sharvansehrawat perspectivereducingsarscov2infectivityanditsassociatedimmunopathology |